Glass House Brands (GLAS) FCF Margin (2020 - 2026)

Glass House Brands (GLAS) posted quarterly FCF Margin of 20.26% for Q1 2026, up 68.62% quarter-over-quarter from 64.56% in Q4 2025.

Glass House Brands (GLAS) FCF Margin (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported FCF Margin for 7 consecutive years, with 20.26% the latest figure, recorded in Q1 2026.

In Q1 2026, FCF Margin changed N/A year-over-year to 20.26%; the TTM figure through Mar 2026 stood at 1.43% (changed N/A YoY), while the FY2025 annual figure was 8.16%, down 85.0% from the prior year.
FCF Margin advanced to 20.26% in Q1 2026 per GLAS's latest filing, from 64.56% in the prior quarter.
Across five years, FCF Margin topped out at 45.43% in Q2 2025 and bottomed at 51705047.73% in Q4 2022.
Historically, FCF Margin has averaged 5170497.93% across 5 years, with a median of 13.66% in 2023.
Annual changes were most pronounced in 2022 — FCF Margin sank 2000000000 bps — and 2025, when it jumped 2167 bps.
Glass House Brands' FCF Margin stood at 51705047.73% in 2022, then soared by 100 bps to 18.04% in 2023, then surged by 32 bps to 23.75% in 2024, then plunged by 372 bps to 64.56% in 2025, then soared by 69 bps to 20.26% in 2026.
Business Quant data shows GLAS's FCF Margin at 20.26% in Q1 2026, 64.56% in Q4 2025, and 9.28% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	7.41%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	21.80%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	14.87%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	26.25%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	8.76%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	13.41%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	17.84%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Glass House Brands	837.25 Mn	818.69 Mn	15.77 Mn	4.49%

Download Data